Correlation between CpG methylation profiles and hormone receptor status in breast cancers by Feng, Weiwei et al.
Open Access
Available online http://breast-cancer-research.com/content/9/4/R57
Page 1 of 13
(page number not for citation purposes)
Vol 9 No 4 Research article
Correlation between CpG methylation profiles and hormone 
receptor status in breast cancers
Weiwei Feng1, Lanlan Shen2, Sijin Wen3, Daniel G Rosen4, Jaroslav Jelinek2, Xin Hu1, 
Shaoyi Huan1, Miao Huang1, Jinsong Liu4, Aysegul A Sahin4, Kelly K Hunt5, Robert C Bast Jr1, 
Yu Shen3, Jean-Pierre J Issa2 and Yinhua Yu1
1Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
2Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
3Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
4Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
5Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Corresponding author: Yinhua Yu, yyu@mdanderson.org
Received: 26 Apr 2007 Revisions requested: 1 Jun 2007 Revisions received: 13 Jul 2007 Accepted: 31 Aug 2007 Published: 31 Aug 2007
Breast Cancer Research 2007, 9:R57 (doi:10.1186/bcr1762)
This article is online at: http://breast-cancer-research.com/content/9/4/R57
© 2007 Feng et al.; licensee BioMed Central Ltd 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction Aberrant DNA methylation has been found
frequently in human breast cancers, associated with the loss of
expression of a number of regulatory genes for growth and
correlated to clinical outcomes. The present study was
undertaken to determine whether methylation of a set of growth-
suppressor genes would correlate to the expression of estrogen
receptors (ERs) and progesterone receptors (PRs).
Methods We used a pyrosequencing methylation analysis to
study the methylation of 12 known growth-suppressor genes in
90 pairs of malignant/normal breast tissues. We also examined
the expression of ERs and PRs in those specimens by
immunohistochemistry. Mutations of p53 in tumor cells were
detected by direct sequencing.
Results Twelve tumor-suppressor genes: ARHI,  RASSF1A,
HIN-1, RARβ2, hMLH1, 14-3-3 σ, RIZ1, p16, E-cadherin, RIL,
CDH13, and NKD2 were selected for this methylation study.
Five of them (RIL, HIN-1,  RASSF1A,  CDH13, and RARβ2)
were frequently methylated in breast cancers (57%, 49%, 58%,
44%, and 17%, respectively) but not the normal breast (0–4%).
Two panels of methylation profiles were defined. The
methylation of the HIN-1/RASSFIA panel strongly correlated to
the expression of ERs, PRs, and hormone receptors (HRs;
which were defined as 'positive' if ERs and/or PRs were
positive; p < 0.001). Conversely, the methylation of the RIL/
CDH13 panel strongly correlated to negative ER, PR, and HR
expression (p = 0.001, 0.025, and 0.001, respectively). The
subset of triple-negative breast cancers (in other words, those
with negative ER, PR, and HER-2/neu status) was positively
associated with the methylation of the RIL/CDH13 panel and
negatively associated with the HIN-1/RASSF1A  panel.
Mutations of p53 were found in nine breast tumors (11%), seven
of which lacked methylation in both panels.
Conclusion We have defined two panels (HIN-1/RASSFIA,
and  RIL/CDH13) of methylation profiles, which correlated,
either positively or negatively, to HR status.
Introduction
Over the past ten years, aberrant DNA methylation has been
recognized as one of the most common molecular abnormali-
ties in breast cancer [1,2]. A large body of evidence implicates
potential hypermethylation of CpG islands in the loss of
expression of a variety of crucial genes. Tumor-suppressor
genes with aberrant methylation in breast cancers include
ARHI [3,4], RASSF1A [5], HIN-1 [6], the retinoic acid recep-
tor II gene (RARβ2) [7], hMLH1 [8], 14-3-3 σ [9], RIZ1 [10],
p16 [11], the E-cadherin gene [12], PTEN [13], and BRCA1
[14]. Methylation in breast cancer has been related to clinical
and pathologic characteristics evident at presentation and
clinical outcomes. A higher prevalence of HIN-1 and RAR β2
methylation was found in the lymph nodes, bone, brain, and
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lung metastases than the primary tumor [15]. Widschwendter
and colleagues [16] reported that the methylation of certain
genes was associated with hormone receptor (HR) status, in
addition to the response to treatment with tamoxifen. A high
prevalence of PGR, HSD17B4, and CDH13 methylation has
been associated with HER-2/neu-positive breast cancer [17].
Methylation-specific PCR (MSP) is a sensitive assay used to
detect methylation and analyze the methylation status of genes
of interest. However, problems inherent to this assay (such as
those caused by the use of different primers for the methylated
or unmethylated alleles, the gel-based data analysis system
used, and difficulties in quantitation) have caused frequent
false-positive results in tissue-sample analyses. A new tech-
nique, pyrosequencing, has been adapted for use in highly
sensitive and quantitative methylation analyses [18,19]. Pyro-
sequencing methylation analysis is a modification of the com-
bined bisulfite restriction analysis (COBRA) that compares
favorably with COBRA in sensitivity, specificity, and robust-
ness [18]. Tost and colleagues also confirmed that the pyro-
sequencing technique is quantitative, amenable to the analysis
of bisulfite-treated DNA derived from paraffin-embedded tis-
sue samples, highly reproducible, and accurate [19]. Bisulfite
pyrosequencing has been used in clinical trials of hypomethyl-
ating drug treatment and provides accurate and reliable
results [20].
To investigate methylation profiles in breast cancer cells, we
used bisulfite pyrosequencing to screen 12 known tumor-sup-
pressor genes in 90 pairs of breast cancers and normal tis-
sues. Although all 12 genes had been reported to exhibit
hypermethylation in a fraction of breast cancer cases, our
assays provided a comprehensive survey of their methylation
status and confirmed that five genes could be useful in defin-
ing a methylation profile in breast cancer cells. Our findings
also suggest that two panels of methylation profiles correlated,
either positively or negatively, to HR status.
Materials and methods
Cell lines
Human breast cancer cell lines SKBr3, MDA-MB-435, MDA-
MB-468, BT-20, MDA-MB-231, and MCF-7 were maintained
in RPMI 1640 medium supplemented with 10% fetal bovine
serum. Normal breast epithelial cells, HMEC 231 and
HMEC234, were cultured in a 1:1 solution of MCDB 105 and
medium 199 with 15% fetal bovine serum and 10 ng/ml epi-
thelial growth factor (Sigma, St Louis, MO, USA), as
described elsewhere [21].
Tissue samples
We used 90 samples, consisting of paired tissues and asso-
ciated clinicopathologic data from the Breast Tumor Bank at
The University of Texas MD Anderson Cancer Center (Hou-
ston, TX, USA). The samples of breast tumors and corre-
sponding adjacent normal-appearing tissues (from tissues
located at least 3 cm away from the site at which the tumor
was sampled) came from 80 patients who had undergone sur-
gery at The University of Texas MD Anderson Cancer Center
in 2004 or 2005 and 10 patients who had been diagnosed
with breast cancer between 1995 and 2003. All tissue sam-
ples had been fresh-frozen and stored at -80°C. No patient
was recruited specifically for this study. All patients gave writ-
ten informed consent permitting the use of their breast tissue
for research at the time specimens were collected. This study
was approved by The University of Texas MD Anderson Can-
cer Center's Institutional Review Board.
Histopathologic analysis
All breast specimens were reviewed by experienced patholo-
gists. Slides were subject to immunoperoxidase staining for
estrogen receptors (ERs; clone 6F11, Novocastra Laborato-
ries Ltd, Benton Lane, UK) and progesterone receptors (PRs;
clone1A6, Novocastra Laboratories Ltd), according to the
manufacturer's recommendations. Cancers were considered
receptor-positive if > 10% of malignant cells showed nuclear
staining. Cancers were classified as HR-positive if the ER and/
or PR status was positive. HER-2/neu gene amplification was
assessed by interphase fluorescence in situ hybridization
(FISH) using the PathVysion HER-2/neu probe kit (Vysis Inc.,
Downers Grove, IL, USA), according to the manufacturer's
recommendations. Levels of the HER-2/neu:CEP17  signal
ratio were considered normal if FISH detected ≤ 2.0 copies
per cell.
Microdissection, DNA extraction, and sodium bisulfite 
treatment
To avoid contamination with normal tissues in the methylation
analysis, we isolated breast cancer cells and paired normal
breast epithelial cells from tissues by manual microdissection,
following the National Cancer Institutes (Bethesda, MA, USA)
protocols [22]. In brief, 5–10 μm sections were cut from each
archival fresh-frozen tissue block. For each pair of tissues, the
presence of tumor cells in malignant tissues and absence of
cancer cells in normal tissues were confirmed by histopatho-
logic examination. Frozen tissue sections were fixed with eth-
anol, stained with H & E, and microdissected using a needle.
Each tumor sample contained > 70% tumor cells after micro-
dissection. Genomic DNA was extracted from patient sam-
ples, breast cancer cell lines, and normal breast epithelial cells
using the Dneasy tissue kit (Qiagen, Valencia, CA, USA).
Bisulfite treatment of 1–2 μg of genomic DNA was performed,
as previously described [3].
Genes studied
Twelve tumor-suppressor genes were selected for this study.
ARHI (CpG I and II), RASSF1A, HIN-1 (SCGB3A1), RARβ2,
hMLH1, the 14-3-3 σ gene, RIZ1, p16 (CDKN2A), and the E-
cadherin gene (CDH1) were selected on the basis of previous
reports of elevated methylation rates in breast cancers [3-12].
RIL (PDLIM4) [23], CDH13, and NKD2 were identified asAvailable online http://breast-cancer-research.com/content/9/4/R57
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hypermethylated genes using genome-wide methylated CpG
island amplification (MCA) from multiple tumors (24). Global
methylation was estimated by testing methylation levels of
LINE1 repetitive elements [25]. We also assessed the meth-
ylation of ERα and PGRB genes.
Pyrosequencing methylation analysis
Bisulfite pyrosequencing was used to detect methylation of all
15 genes. Pyrosequencing primers were designed using
Assay Design software 1.0 (Biotage, Westborough, MA,
USA). For each gene, we selected the CpG island region
flanking the transcription start site at the 5'UTR. Two to six
CpG sites were studied for each particular CpG island. The
primers for pyrosequencing and PCR conditions are listed in
Additional file 1. Bisulfite-treated DNA (1 μl) was amplified in
50 μl of reaction mixture, containing primers and 0.2 U of Taq
polymerase (New England Biolabs, Ipswich, MA, USA). For
the amplification of HIN-1,  RARβ2,  hMLH1, the 14-3-3 σ
gene, RIZ1, the E-cadherin gene, NKD2, and PGRB, we used
a universal primer approach [18]. The PCR product was puri-
fied and methylation was quantitated using the PSQ HS 96A
pyrosequencing system and Pyro gold reagents (Biotage).
Methylation data are presented as the percentage of average
methylation in all observed CpG sites. To set the controls for
pyrosequencing, we used cancer cell lines and normal cells
that were consistently positive or negative with stable levels of
methylation. In this study, each PCR assay included a positive
control (the MDA-MB-231 breast cancer cell line, which is
highly methylated in most genes) and a negative control (nor-
mal breast epithelial cells, HMEC231, which are unmethylated
in all genes, except LINE1, ARHI, and the 14-3-3 σ gene).
RKO, a colon cancer cell line that is highly methylated in
hMLH1 and p16, was also used as a positive control.
p53 mutation detection
Genomic DNA was extracted from microdissected tumor tis-
sue using the QIAGEN DNA purification kit (Qiagen). PCR
was performed using primers that amplify p53 exons 5–6 and
7–9. The PCR products were then purified by the gel purifica-
tion system (Qiagen) or Exonuclease I and shrimp alkaline
phosphatase (USB, Cleveland, OH, USA). Mutations were
determined by direct sequencing.
Statistical methods and analysis
In the studied cohort, adjacent normal breast tissue was taken
from each of 90 patients during surgery. Taking advantage of
paired normal/tumor samples in this study, we chose the value
of normal samples as the reference. If using the sample mean
plus two times the standard deviation of the pooled normal
samples (and a minimum of 10% methylation) as a cut-off
point, there is > 97% probability that the methylation level for
a normal tissue will be lower than the cut-off point. It is reason-
able to assume that a value larger than the cut-off point is likely
to be abnormal (or positive). Panels of genes, that is to say,
HIN-1/RASSF1A and RIL/CDH13 were considered positive
if both markers in each panel were positive. Descriptive analy-
ses were performed first for exploratory purposes. Pair-wise
scatter plots are presented to show the correlations among
the genes methylated. Heat maps were plotted to show levels
of gene expression or methylation using hierarchical clustering
to visually represent the association of different genes or sam-
ples by histopathologic tumor characteristics (ERs, PRs, and
HER-2/neu). Chi-square or Fisher's exact test were used to
assess the dependence between two categorical variables.
Pearson's correlation coefficient was used to assess the rela-
tionship between two continuous variables. The Wilcoxon
rank-sum test was used to compare either continuous or cate-
gorical variables between two groups. Analysis of variance
(ANOVA) was applied to compare the values of gene methyl-
ation with tumor characteristics. Multivariate logistic regres-
sion was used to assess the ability of various levels of gene
methylation to predict the ER, PR, HR, or HER-2/neu status.
All reported p values are two-sided and considered statisti-
cally significant if p < 0.05. Analyses were performed using S-
PLUS 2000 software (Insightful Corp., Seattle, WA, USA).
Results
Patients' clinical data
Patient characteristics are presented in Table 1. Normal paired
tissues were unavailable in two cases. Information regarding
the grade, HER-2/neu status, and ER and PR status were una-
vailable for one, ten, and three patients, respectively.
Accuracy, reproducibility, and quantitation of results 
with bisulfite pyrosequencing
To confirm the reliability of bisulfite pyrosequencing for the
quantitation of methylation levels, we measured the methyla-
tion of ARHI CpG islands I and II using pyrosequencing and
COBRA and compared the resulting data. COBRA detected
only one CpG site, whereas pyrosequencing detected four to
eight CpG sites in one CpG island (Figure 1). From six breast
cancer cell lines and two cultures of normal breast epithelial
cells, methylation data were matched in CpG island II but not
completely matched in CpG island I. COBRA showed two
breast cancer cell lines were partially methylated in CpG
island I (50% and 54% in one CpG site), but they were shown
to be hypermethylated in CpG island I by pyrosequencing (the
mean of four CpG sites per island was 92% and 91%, respec-
tively). On the basis of these results, pyrosequencing was
more sensitive for methylation detection than COBRA.
To confirm the reproducibility of pyrosequencing, the methyla-
tion of HIN-1 and RIL was measured repeatedly in 22 samples
using bisulfite treatment and pyrosequencing assays. The cor-
relation between repeated and initial values was high (for HIN-
1, Pearson's correlation coefficient R = 0.99 and p < 0.0001;
for RIL, R = 0.99 and p < 0.0001). In addition, the variation
between individual assays was < 6%: the mean differences
and 95% confidence intervals (CIs) for HIN-1 and RIL wereBreast Cancer Research    Vol 9 No 4    Feng et al.
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Table 1
Patient characteristics
Clinicopathologic factors Number of sample
Age 90
Median, range 57 years, 29–81 years
Tumor grade (BNG) 89
13
24 7
33 9
Tumor size 90
T1 19
T2 36
T3 18
T4 17
Stage 90
I1 5
II 37
III 38
Lymph-node metastasis 90
pN0 39
pN1 28
pN2 9
pN3 14
Lymphatic invasion 78
Positive 33
Negative 45
Vascular invasion 78
Positive 32
Negative 46
ER status 87
Positive 52
Negative 35
PR status 87
Positive 40
Negative 47
Hormone receptor status 87
Positive (ER- and/or PR-positive) 55
Negative (both ER- and PR-negative) 32
HER-2/neu status 80
Positive 7
Negative 73
Histology 90
Ductal 62
Lobular 8
Mixed ductal and lobular 9
Other 11
BNG, Black's nuclear grade; ER, estrogen receptor; PR, 
progesterone receptor.
Table 1 (Continued)
Patient characteristicsAvailable online http://breast-cancer-research.com/content/9/4/R57
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1.9% with 95% CIs of -0.1% to 3.9% and 3.0% with 95% CIs
of 0.1% to 6.0%, respectively.
Frequent methylation of RIL, HIN-1, RASSF1A, CDH13, 
and RARβ2
We evaluated the methylation status of 12 putative tumor-sup-
pressor genes (ARHI, RASSF1A, HIN-1, RARβ2, hMLH1, the
14-3-3 σ gene, RIZ1, p16, the E-cadherin gene, RIL, CDH13,
and NKD2), LINE1, ER, and PGRB in both culture cell lines
and primary cancer tissues. The results from the analysis of six
breast cancer cell lines and two normal breast epithelial cell
samples (Additional file 2) indicated that 7 of 12 genes (RIL,
HIN-1, RASSF1A, ARHI, CDH13, RARβ2, and NKD2) were
densely methylated (marked bold) in cancer cell lines but not
in normal breast epithelial cell lines. We also tested the meth-
ylation profiles of the 12 genes in breast cancer and the adja-
cent normal breast tissues from the same patients. In our pilot
study, we screened 12 tumor-suppressor genes in 32–37
paired tissues. Five tumor-suppressor genes (RASSF1A, RIL,
HIN-1, CDH13, and RARβ2) were frequently methylated in
breast cancer tissues (the positive rate ranged from 17% to
58%) but not in normal breast tissues (the positive rate ranged
from 0% to 4.5%). Another five genes (RIZ1, the E-cadherin
gene, p16, hMLH1, and NKD2) were not frequently methyl-
ated in either malignant or normal breast tissue (the positive
rate ranged from 0% to 9%, all < 10%). The 14-3-3 σ gene is
highly methylated in both malignant and normal breast tissues.
ARHI, as an imprinted gene, is at least partially methylated in
all cases (Figure 2 and Table 2). Consequently, seven genes
were unsuitable for development of methylation profiles. To
correlate the methylation profile to clinical outcomes, we
focused on the five highly methylated genes by assaying 53
more paired samples. PGRB was not frequently methylated in
the 48 cases of breast tumor or normal breast tissue. ER was
not highly methylated in the 40 cases of breast tumor or nor-
mal breast tissue, but higher methylation levels were observed
in normal tissues. LINE1, a global methylation marker, was
highly methylated in all normal and malignant tissues, but the
methylation levels were significant lower in tumors (60.0 ±
8.8) than normal tissues (68.2 ± 3.5; p < 0.001).
Figure 1
Pyrosequencing analysis for ARHI methylation Pyrosequencing analysis for ARHI methylation. (a) Design of pyrosequencing primers for ARHI CpG islands I and II. The vertical bars indicate CpG 
sites in PCR products. COBRA indicated the restriction enzyme cutting site. (b) Pyrosequencing results for ARHI CpG island II methylation in MB-
MDA-231 cells using two detection primers (Pyro F1 and F2). Methylation levels ranged from 65% to 100%, with a mean of 84%. Gray highlighting 
marks the CpG sites tested and the percentage reading of C and T. COBRA, combined bisulfite restriction analysis.Breast Cancer Research    Vol 9 No 4    Feng et al.
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Correlation of methylation between different genes and 
to age
On the basis of data from continuous marker methylation anal-
yses in normal tissues, the methylation levels of RASSF1A and
HIN-1 exhibited a strong correlation to each other (R = 0.66,
p < 0.001). Some moderate correlations were found between
RARβ2 and CDH13 (R = 0.40, p < 0.001) and between RIL
and CDH13 (R = 0.30, p = 0.004). Similarly, in tumor tissues,
a moderate correlation existed between RASSF1A and HIN-1
(R = 0.51, p < 0.001) and a weak correlation existed between
RIL and CDH13 (R = 0.19, p = 0.068). In addition, the global
methylation marker LINE1 was negatively correlated to RIL (R
= -0.25, p = 0.019) and RASSF1A (R = -0.26, p = 0.014) in
breast cancer samples.
In normal tissues, RIL methylation levels increased with age (R
= 0.336, p = 0.001), whereas other markers had little correla-
tion to age. In the cancer tissues, HIN-1 levels exhibited a
weak correlation to age (R = 0.229, p = 0.03), whereas other
markers had little correlation to age.
Correlation between methylation in malignant and 
adjacent normal tissues
To study whether gene methylation in cancer would affect
adjacent normal-appearing mammary gland tissues, the pair-
wise correlation between paired tumor and adjacent normal
breast tissues was estimated for each marker. Methylation of
RIL, HIN-1, RASSF1A, and CDH13 exhibited a positive cor-
relation between breast cancer and normal tissues. The Pear-
son correlation values ranged from 0.25 to 0.38 (p  values
ranged from 0.02 to 0.0002).
Relationship between methylation of individual genes 
and clinical characteristics
Using the ANOVA model, no statistically significant associa-
tions were found between clinical stage, tumor size, or node
status. Tumors that were poorly differentiated (grade 3)
according to Black's nuclear grade (BNG) had lower methyla-
tion levels of HIN-1 than well- and moderately differentiated
tumors (grade 1 + 2; p = 0.01). Similarly, RASSF1A methyla-
tion levels were lower in poorly differentiated cancers than
well- and moderately differentiated tumors (p  = 0.053). In
addition, CDH13 and RIL  methylation levels cancers were
marginally higher in poorly differentiated than well- and moder-
ately differentiated cancers (p  = 0.059 and 0.096,
respectively).
Relationship between methylation of individual genes 
and ER, PR, HR, and HER-2/neu status
In univariate analyses, the ER status was positively associated
with high HIN-1 and RASSF1A methylation levels but nega-
tively correlated to high RIL methylation levels (p < 0.001,
Table 2
Methylation levels of 15 genes from pairs of normal and malignant breast tissues
Gene Number of cases studied Methylation level (mean ± SD) (Positive rate*)
Normal Cancer pvalue**
LINE1 90 68 ± 4 60 ± 9 < 0.001
RIL 90 10 ± 4 (4.5) 27 ± 22 (57) < 0.001
HIN-1 90 5 ± 3 (2.3) 20 ± 20 (49) < 0.001
RASFF1A 90 3 ± 3 (3.4) 19 ± 20 (58) < 0.001
CDH13 90 3 ± 2 (0) 14 ± 13 (44) < 0.001
RARβ2 90 2 ± 1 (0) 7 ± 12 (17) < 0.001
ARHI CpG I 32 30 ± 6 (0) 47 ± 16 (49) < 0.001
ARHI CpG II 32 38 ± 7 (2) 36 ± 10 (2) 0.250
RIZ1 37 2 ± 2 (0) 3 ± 4 (5) 0.111
E-cadherin 34 4 ± 3 (3) 4 ± 4 (9) 0.163
p16 33 2 ± 1 (0) 1 ± 1 (0) 0.044
hMLH1 33 2 ± 3 (6) 1 ± 1 (0) 0.864
14-3-3 σ 10 75 ± 21 60 ± 28 0.275
NKD2 47 2 ± 4 (2) 4 ± 7 (8.5) 0.308
PGRB 48 3 ± 2 (0) 2 ± 3 (0) 0.594
ERα 40 7 ± 4 (3) 5 ± 3 (5) < 0.001
*Positive rate using the sample mean plus two times the SD of the pooled normal samples (and minimum 10% methylation) as a cut-off point.
**p value computed using the Wilcoxon signed rank test for paired data. SD, standard deviation.Available online http://breast-cancer-research.com/content/9/4/R57
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0.002, and 0.01, respectively). Specifically, patients with a
positive ER status had higher methylation levels of HIN-1
(mean of 29% in ER-positive tumors versus 9% in ER-negative
tumors), whereas patients with a negative ER status had
higher methylation levels of RIL (mean of 36% in ER-negative
tumors versus 22% in ER-positive tumors). In addition, the PR
status was positively associated with high HIN-1 methylation
levels (p < 0.001) and negatively associated with high CDH13
methylation levels (p = 0.03). By defining the HR status as
positive if the status of ERs and/or PRs is positive, the associ-
ations between the methylation markers and HRs are similar to
those between the methylation markers and ERs. In multivari-
ate logistic models, high levels of both HIN-1 and RIL methyl-
ation are independent predictors of the status of ERs and
HRs, and high levels of HIN-1 and CDH13 methylation are
independent predictors of PR status (Table 3). Higher methyl-
ation levels of HIN-1 were more likely to be associated with
ER-positive than ER-negative tumors, whereas higher methyl-
ation levels of RIL were more likely to be associated with ER-
negative than ER-positive tumors. Using multivariable logistic
models, we have assessed the effect of each gene (LINE1,
RIL, HIN-1, RASFF1A, CDH13, and RARβ2) on HR (adjusted
for age), ER (adjusted for age and PR status), or PR (adjusted
for age and ER status) status (Additional file 3). The results
shown in Additional file 3 are similar to those in Table 3.
Among the markers studied, the higher methylation levels of
HIN-1 were significantly correlated to a lack of HER-2/neu
amplification (p = 0.014).
Correlation of two panels of methylation profiles to 
opposite hormone status
Because of a correlation between the methylation levels of
several of the genes studied, we assembled four potential
markers into two panels: HIN-1/RASSFIA and RIL/CDH13. A
Figure 2
Comparison of promoter methylation levels of 15 genes in paired normal and malignant breast tissue samples Comparison of promoter methylation levels of 15 genes in paired normal and malignant breast tissue samples.Breast Cancer Research    Vol 9 No 4    Feng et al.
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univariate analysis was performed and a multivariate logistic
model was fitted to the two panels. The results of the univari-
ate analysis for each panel indicated that the panels had a
greater power to predict ER, PR, and HR status (Table 4 and
Figure 3) than the methylation of individual genes (Table 3).
Methylation of the HIN-1/RASSFIA panel was strongly corre-
lated to positive ER, PR, and HR expression; 88% of HIN-1/
RASSFIA-positive breast cancers were ER-positive and only
12% of breast cancers were ER-negative (p < 0.001). Con-
versely, methylation of the RIL/CDH13  panel was strongly
correlated to negative ER, PR, and HR expression, because
69% of methylation-positive tumors were ER-negative and
only 31% were ER-positive (p = 0.001).
We summarize the fitted multivariate logistic models of the
HIN-1/RASSF1A and RIL/CDH13 panels by categorical var-
iables (Table 3). Specifically, a patient with a positive value in
the RIL/CDH13 panel is ten times more likely to have an ER-
negative tumor than a patient with a negative value. By con-
trast, a patient with a positive value in the HIN-1/RASSF1A
panel is 17 times more likely to have an ER-positive tumor than
a patient with a negative value.
Interestingly, we found that triple-negative breast cancers (in
other words, those with negative ER, PR, and HER-2/neu sta-
tus) were positively correlated to methylation of the RIL/
CDH13 panel and negatively correlated to methylation of the
HIN-1/RASSFIA panel (Table 4). In particular, 58% (15 out of
26) of triple-negative cancers exhibited methylation of the RIL/
CDH13 panel, whereas 17% (11 out of 64) of triple-negative
cancers failed to methylate in this panel (p < 0.001). Only 9%
(3 out of 34) of triple-negative cancers exhibited HIN-1/
RASSFIA panel methylation, whereas 41% (23 out of 56) of
triple-negative cancers failed to methylate in this panel (p =
0.001). In addition, triple-negative cancers were significantly
associated with advanced tumor grade (24% in grade 1 and 2
versus 76% in grade 3; p = 0.001).
Breast tumors with p53 mutations lacked methylation
We studied the mutation status of p53 in the 84 tumors in
which DNA sequences were available for analysis. Overall,
p53 mutations were found in 9 out of 84 (11%) cases. Seven
cases with p53 mutations belonged to the group that lacked
methylation in both panels; one case was positive in the HIN-
1/RASSF1A  panel and one case was positive in the RIL/
CDH13 panel. In the methylation-negative group (both panels
were negative), 18% (7 out of 38) of the specimens had p53
mutations; in the methylation-positive group (either panel or
both panels were positive), only 4% (2 out of 46) of specimens
had p53 mutation (p = 0.072 in Fisher's exact test). Interest-
ingly, five of the cases with p53 mutations occurred in triple-
negative (ER-, PR-, and HER2-negative) cancers.
Discussion
Although a large body of evidence has demonstrated that
aberrant DNA methylation has an important role in breast car-
cinogenesis, variation in the data is still a problem. In this
study, we used bisulfite pyrosequencing to quantitate the
methylation of 12 known tumor-suppressor genes in breast
cancers. To avoid contamination with normal tissues, we iso-
lated breast cancer cells by microdissection and compared
levels of methylation with those in normal breast epithelial cells
from the same patients. Bisulfite pyrosequencing provided
sensitive and reproducible measurements. The variation
between the different assays was < 6%. Our data confirmed
that RIL, HIN-1, RASSF1A, CDH13, and RARβ2 were fre-
quently methylated in breast cancers but not in normal breast
tissues. The other six genes were not highly methylated in
breast cancers or methylated in either malignant and normal
breast tissues; ARHI, as an imprinted gene, has a different
Table 3
Fitted multivariate logistic models for ER, PR, and HR expression
Single gene model Two-panels model
Odds ratio (95% CI) pvalue Odds ratio (95% CI) pvalue
ER ER
HIN-1 (× 10-1) 0.399 (0.25 to 0.63) 0.0001 HIN-1/RASSF1A 0.06 (0.01 to 0.25) < 0.0001
RIL (× 10-1) 1.525 (1.11 to 2.10) 0.0094 CDH13/RIL 10.14 (2.65 to 38.76) 0.001
PR PR
HIN-1 (× 10-1) 0.551 (0.41 to 0.74) 0.0001 HIN-1/RASSF1A 0.17 (0.06 to 0.46) < 0.0001
CDH13 (× 10-1) 1.674 (1.05 to 2.67) 0.0305 CDH13/RIL 3.51 (1.17 to 10.51) 0.025
HR HR
HIN-1 (× 10-1) 0.319 (0.18 to 0.57) 0.0001 HIN-1/RASSF1A 0.05 (0.01 to 0.23) < 0.0001
RIL (× 10-1) 1.481 (1.08 to 2.03) 0.0153 CDH13/RIL 10.18 (2.67 to 38.81) 0.001
CI, confidence interval; ER, estrogen receptor; HR, hormone receptor; PR, progesterone receptor.Available online http://breast-cancer-research.com/content/9/4/R57
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Table 4
Univariate analysis of clinical variables by HIN-1/RASSF1A and RIL/CDH13panels, according to Fisher's exact test
HIN-1/RASSF1A panel RIL/CDH13 panel
Number negative 
(percentage)
Number positive 
(percentage)
p value Number negative 
(percentage)
Number positive 
(percentage)
p value
Tumor size 0.502 0.999
1 11 (20) 8 (24) 14 (22) 5 (19)
2 20 (36) 16 (47) 25 (39) 11 (42)
3 12 (21) 6 (18) 13 (20) 5 (19)
4 13 (23) 4 (12) 12 (19) 5 (19)
Tumor grade (BNG) 0.015 0.162
1 + 2 25 (45) 25 (74) 39 (61) 11 (44)
3 30 (55) 9 (26) 25 (39) 14 (56)
Tumor stage 0.16 0.745
1 8 (14) 7 (21) 12 (19) 3 (12)
2 20 (36) 17 (50) 25 (39) 12 (46)
3 28 (50) 10 (29) 27 (42) 11 (42)
Lymph-node metastasis 0.558 0.78
PN0 24 (43) 15 (44) 26 (41) 13 (50)
PN1 16 (29) 12 (35) 22 (34) 6 (23)
PN2 5 (9) 4 (12) 6 (9) 3 (12)
PN3 11 (20) 3 (9) 10 (16) 4 (15)
Lymphatic invasion 0.244 0.805
1 25 (52) 20 (67) 32 (59) 13 (54)
2 23 (48) 10 (33) 22 (41) 11 (46)
Vascular invasion 0.346 0.623
1 26 (54) 20 (67) 33 (61) 13 (54)
2 22 (46) 10 (33) 21 (39) 11 (46)
ER status < 0.001 0.001
Positive 22 (42) 30 (88) 44 (72) 8 (31)
Negative 31 (58) 4 (12) 17 (28) 18 (69)
PR status < 0.001 0.033
Positive 16 (30) 24 (71) 33 (54) 7 (27)
Negative 37 (70) 10 (29) 28 (46) 19 (73)
HR status < 0.001 0.001
Positive 24 (45) 31 (91) 46 (75) 9 (35)
Negative 29 (55) 3 (9) 15 (25) 17 (65)
HER-2/neu status 0.041 0.999
Positive 7 (14) 0 (0) 5 (9) 2 (8)
Negative 43 (86) 30 (100) 50 (91) 23 (92)
Triple-negative 0.001 < 0.001
No 33 (59) 31 (91) 53 (83) 11 (42)
Yes 23 (41) 3 (9) 11 (17) 15 (58)
BNG, Black's nuclear grade; ER, estrogen receptor; HR, hormone receptor; PR, progesterone receptor.Breast Cancer Research    Vol 9 No 4    Feng et al.
Page 10 of 13
(page number not for citation purposes)
methylation status. All the inconsistencies indicate that these
seven genes are unsuitable for methylation profile studies.
In the past, methylation data have been correlated to clinical
pathologic parameters, to clarify the role of methylation in
breast carcinogenesis. Our most interesting finding was a cor-
relation between gene methylation and the HR status. Methyl-
ation in breast cancer has already been connected to hormone
regulation, but the correlation is not clear yet. Campan and col-
leagues [26] reviewed the DNA methylation profiles of breast,
endometrial, ovarian, and proximal colon cancers but did not
find evidence for global hormone-specific DNA methylation
alterations. Widschwendter and colleagues [16] reported sig-
nificant differences in the HR status between clusters of DNA
methylation profiles. Their results suggested the existence of
an interaction between DNA methylation and HR biology in
breast cancer cells. In our own study, we found that the ER
status was positively associated with the methylation of HIN-1
and RASSF1A but negatively correlated to the methylation of
RIL. In addition, the PR status was positively associated with
the methylation of HIN-1 and negatively associated with the
methylation of CDH13. Moreover, if data from the methylation
of individual genes were combined into two panels, methyla-
tion of the HIN-1/RASSF1A  panel strongly predicted the
expression of ERs, PRs, and HRs and methylation of the RIL/
CDH13 panel strongly predicted the negative expression of
ERs, PRs, and HRs.
The status of ERs, PRs, and HRs has been recognized as an
important prognostic factor in patients with breast cancer, in
addition to a predictive marker for the response to treatment
with endocrine therapy. The presence of ERs and/or PRs is
predictive of the response to treatment with the antiestrogen
tamoxifen [27]. ER and PR expression patterns are heavily
influenced by changes in the chromatin structure during tran-
scription. Indeed, both the predominant mammalian DNA
methyltransferase and histone deacetylases have crucial roles
in maintaining transcriptionally repressive chromatin by form-
ing suppressive complexes at replication foci [28]. Our current
Figure 3
Comparison of two methylation panels with hormone receptor status Comparison of two methylation panels with hormone receptor status. (a) Dichotomous heat map representing DNA methylation in the HIN-1/
RASSF1A panel (left) and hormone status of each tumor (right). (b) Dichotomous heat map representing DNA methylation data in the RIL/CDH13 
panel (left) and hormone receptor status of each tumor (right). Dark gray, positive; light gray, negative.Available online http://breast-cancer-research.com/content/9/4/R57
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studies provide evidence that epigenetic changes are tightly
connected with HR regulation in breast cancer.
Interestingly, ERs and PRs were not frequently methylated in
breast cancers at levels comparable with those observed in
the five tumor-suppressor genes. Consequently, alterations in
methylation do not seem to have silenced these receptors
directly. Increased methylation of certain genes was associ-
ated with the expression of ERs and PRs, suggesting that
silencing of, at least some, tumor suppressors might affect the
transcriptional regulation of HRs, possibly by upregulating HR
co-stimulators. Conversely, the downregulation of ERs or PRs
might relate to the increased expression of HR co-repressors.
These hypotheses will be tested in future studies.
Recently, on the basis of the microarray profiling of invasive
breast carcinomas, five distinct subtypes of tumors (luminal A,
luminal B, normal breast-like, HER-2/neu overexpressing, and
basal) associated with different clinical outcomes have been
identified [29,30]. The basal subtype is associated with poor
clinical outcomes and the subtype observed in BRCA1-
related breast cancers. All basal-like tumors tested in the cur-
rent study were triple-negative (that is to say, negative for ER,
PR, and HER-2/neu expression), poorly differentiated, and
high-grade [29,30]. An early study of HIN-1  methylation
revealed lower frequencies of HIN-1 promoter methylation in
sporadic breast tumors with a 'BRCA1-like' histopathologic
phenotype [31]. In the 90 cases we tested, 76% of the 26 tri-
ple-negative tumors were high-grade. Interestingly, we found
these tumors to be positively associated with methylation of
the RIL/CDH13 panel but negatively correlated to methylation
of the HIN-1/RASSFIA  panel. Our results suggested that
methylation reflected by the RIL/CDH13 panel might have a
role in the phenotype of basal-like breast tumors.
Recent advances in molecular biology have revealed numer-
ous genetic alterations involved in breast tumorigenesis; p53
mutation is among the most important of those alterations, and
studies have reported that p53 mutations are strongly associ-
ated with poor prognoses in breast cancer [32]. In colorectal
cancer, methylation phenotypes define two groups with signif-
icantly different genetic lesions (K-RAS and p53 mutations)
[33]. In this study, we have identified 11% of breast tumors
that had p53 mutations. Equivalent to the observation in color-
ectal cancers, most cases with p53 mutations belong to the
group that lack methylation, suggesting that p53 mutation and
methylation can be two distinct mechanisms that deactivate
tumor-suppressor genes in breast cancer. The correlation of
p53 mutation to hypomethylation is also likely to be owing to
the fact that p53 mutations and hypomethylation both occur in
basal-like triple-negative breast cancers.
The methylation of multiple tumor-suppressor genes has been
correlated to poor prognoses in cancers [34]. The use of epi-
genetic information has shown promise in the identification of
patients with gastrointestinal cancers who have poor prog-
noses [35]. In esophageal carcinoma, the cancers with fre-
quent methylation had significantly poorer survival, and
methylation was a better predictor of outcome than the dis-
ease stage or patient age [36]. Methylation, as a prognosis
factor, has also been described in bladder cancer [37], head
and neck cancer [38], ovarian cancer [39], and acute lym-
phocytic leukemia [40]. In our study, we did not have sufficient
survival data to correlate methylation to prognosis (most
patients were treated in 2004 and 2005), but we did confirm
that the methylation of multiple tumor-suppressor genes was
an early event in the subgroups of patients with breast cancer.
To understand whether methylation is a prognostic factor in
breast cancer, we must conduct studies with longer follow-up
times to obtain adequate survival data.
Finally, epigenetic therapy, including the use of demethylating
agents (for example, 5-aza-cytidine and 5-aza-2'-deoxycyti-
dine) and histone deacetylase inhibitors (for example, suberoy-
lanilide hydroxamic acid and valproic acid), is currently in
clinical trials for myelodysplastic syndrome, leukemia, ovarian
cancer, and lung cancer. Previous reports indicate that the
'cross-talk' between inhibitors of DNA methylation and histone
deacetylase can result in synergistic activation of silent tumor-
suppressor genes in breast cancer. These observations sug-
gest that combination of these inhibitors might be an effective
form of epigenetic therapy for breast cancer. It is possible that
epigenetic therapy will have a role in the management of
breast cancer. The information from this study of methylation
profiles will be useful for the study of the biology of breast can-
cer and refining epigenetic therapy.
Conclusion
By pyrosequencing methylation analysis, we have examined
the methylation profile of 90 normal/breast cancer paired
samples. Our data indicated that 5 out of 12 tumor-suppressor
genes were frequently methylated in breast cancers but not
the normal breast. We have defined two panels (HIN-1/
RASSFIA and RIL/CDH13) of methylation profiles, which cor-
related, either positively or negatively, to HR status.
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